At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories. That it depends thereby less on large names, but on the future potential and whether the market also recognizes these perspectives, was one of its first learnings at the stock exchange.
On these pages, Nico examines current events at listed companies and takes a closer look at companies that are traded under the radar of the market, in addition to well-known securities.
In order to be able to take advantage of speculative opportunities on the stock exchange, Nico not only focuses on a balanced asset allocation of defensive and opportunity-oriented securities, but also on an intact risk management. "In addition to position size and entry in several tranches, investors should also develop a sense of timing and get to know a stock better before investing," says the columnist.
Commented by Nico Popp
Commented by Nico Popp on April 17th, 2023 | 09:30 CEST
E-car surprise in China: Mercedes-Benz, BYD, Grid Metals
E-cars? Yes, please! At least, that is the case for Mercedes CEO Ola Källenius. He sees his company clearly focused on the electric drive - regardless of technology openness. This seems to be paying off at Mercedes: In the first quarter, the Swabians sold almost twice as many e-cars as in the previous year. But how far can this growth go? What do the absolute figures say? We make the comparison and outline investment opportunities.
Read
Commented by Nico Popp on April 14th, 2023 | 10:38 CEST
Opportunity-oriented investing: Barrick Gold, Canadian North Resources, Steinhoff
Inflation in the US is rising less quickly than expected - but what is the gold price doing? It remains at a high level. The reason is that the situation in many currency areas remains tense. The Eurozone, for example, is still far from inflation rates with a five before the decimal point. Investors should therefore continue to keep gold and commodities on their radar. We show which investments could be worthwhile.
Read
Commented by Nico Popp on April 6th, 2023 | 09:44 CEST
Energy turnaround for your portfolio: RWE, GoviEx Uranium, Nordex
Clean energy is a dream for humanity. Property owners can fulfil the dream of clean energy by installing photovoltaic systems. But what about when large industrial companies, such as BASF, need electricity? While renewable energy has to be stored temporarily, nuclear power plants deliver reliably. The technology, which is frowned upon in Germany, is currently experiencing a revival worldwide. We explain which forms of energy also have a future for investors.
Read
Commented by Nico Popp on April 5th, 2023 | 12:30 CEST
Crisis comeback? There is a solution! Deutsche Bank, Vonovia, Globex Mining
March was a dark month for the shares of Deutsche Bank and Vonovia - the prices of both companies fell by more than 20%. In recent weeks, the uncertainty surrounding banks and real estate companies was too great. At the same time, the gold price rose significantly and even surpassed the USD 2,000 mark. We look at what the contrasting price movements mean and where laggards can be found.
Read
Commented by Nico Popp on April 5th, 2023 | 08:05 CEST
Opportunities for latecomers: Rheinmetall, BYD, Almonty Industries
The Rheinmetall share has been on a rollercoaster ride since the outbreak of the war in Ukraine. Recently, however, the share price has risen significantly. We explain the further perspective, provide alternatives, and shed light on a possible insider tip. In advance, it should be noted the opportunities beyond well-known stocks are great. However, investors need to consider a few details.
Read
Commented by Nico Popp on April 4th, 2023 | 17:04 CEST
Race against cancer: BioNTech, Bayer, Defence Therapeutics
BioNTech first became known to the general public about three years ago. At that time, the pandemic was rampant and the first vaccine plans were making the rounds in the media. Among all the big names, BioNTech was initially one of many options for the public. In the meantime, the Company has become so dominant in Germany that the competition has been left behind. We look at what this means for investors and the pharmaceutical industry.
Read
Commented by Nico Popp on April 3rd, 2023 | 15:59 CEST
Range of up to 2,000 km - Hydrogen comeback? Volkswagen, dynaCERT, NEL
Car manufacturers like Volkswagen apply for a whole series of patents every year. Many of them never become relevant. A few months ago, however, Volkswagen and a partner company filed a hydrogen patent that is quite something. There is talk of a fuel cell that, thanks to a ceramic membrane, is more efficient and enables ranges of up to 2,000 km for one tankful. Will the patent bring about the hydrogen revolution in private transport? We analyse the situation and look at three listed companies.
Read
Commented by Nico Popp on March 29th, 2023 | 08:15 CEST
Market failure! Highs and lows at BASF, Myriad Uranium, Vonovia
We all know efficient markets from the textbook. There, buyers and sellers always come together - and in the end, there is no apple left over. In reality, markets are highly complex and are sometimes dependent on external factors that can change everything overnight. Today we look at BASF's business in China, the real estate market and the emerging market for uranium.
Read
Commented by Nico Popp on March 28th, 2023 | 07:36 CEST
E-cars - Out of a dream! BYD, BMW, First Phosphate
While German politicians are still discussing the end of the internal combustion engine, major car companies have long since made up their minds. The future is electric. But the mobility revolution is far from being a done deal! We explain where there are still pitfalls and why a small company from Canada could soon be sitting at the big levers to make the dream of clean e-mobility come true for everyone.
Read
Commented by Nico Popp on March 27th, 2023 | 09:26 CEST
Cost pressure in the healthcare system - how you benefit: Bayer, BioNxt, BioNTech
What do you think of the German healthcare system? While doctors regularly grumble about bureaucracy and patients about long waiting times or other inconsistencies, a new divide is opening up between pharmaceutical companies. Research-based pharmaceutical companies favour long patent protection, while generics manufacturers want more lax rules. We explain the system and highlight opportunities for investors.
Read